Remdesivir.
Alright, so I guess remdesivir is out and about for real this week. Good. I don't know if it sufficiently effective to change the picture much but we will know soon.
As I have said about hydroxy, remdesivir, plasma transfers etc, I am not married to any of them. I just want to shorten the cycle for looking at them for real and either start using them more or set them aside. I dont want to hear about how remdesivir is coming for the next year and how it may or may not help. Git her out there and git it over with as far as having a decent look-see.
And yes if we dont study these first for the next ten years as Dr. Fauci would like then probably someone's dick will fall off. We are talking battlefield medicine here. Actually Fauci is on board because Gilead paid the NIH which Fauci directs to do an in-house drug trial. Now Fauci is smiling because it is "his study" and his shiite does not stink and resdemsivir cleary has benefits because his study says so. Whatever. These guys know how to play the game. Just git er done.
“They will begin shipping tens of thousands of treatment courses out early this week and be adjusting that as the epidemic shifts and evolves in different parts, in different cities here in the United States,” he said.
https://www.foxnews.com/science/cor...vir-reach-patients-this-week-developer-gilead
It should be noted that despite claims by Internet pundits that Gilead is charging $4500 per dose of remdesivir. This is not true.
Gilead CEO says remdesivir will be available to patients this week: ‘We’ve donated the entire supply’
https://www.cnbc.com/2020/05/03/gil...this-week-weve-donated-the-entire-supply.html
- Gilead’s antiviral drug — remdesivir — has shown success in helping coronavirus patients recover faster.
- “We intend to get [remdesivir] to patients in the early part of this next week, beginning to work with the government which will determine which cities are most vulnerable and where the patients are that need this medicine,” Gilead Sciences chairman and CEO Daniel O’Day told CBS’ “Face of the Nation.”
- Gilead Sciences donated its entire supply of the drug to the U.S. government.
Gilead Sciences’ coronavirus fighting drug will be in the hands of doctors and patients as early as this week, the biotechnology company’s CEO said Sunday.
“We intend to get [remdesivir] to patients in the early part of this next week, beginning to work with the government which will determine which cities are most vulnerable and where the patients are that need this medicine,” Gilead Sciences chairman and CEO Daniel O’Day told CBS’ “Face of the Nation.”
“We’ve donated the entire supply that we have within our supply chain and we did that because we acknowledge and recognize the human suffering, the human need here, and want to make sure nothing gets in the way of this getting to patients,” O’Day added.
The
deadly coronavirus has caused unprecedented societal and financial disruption in the U.S. and worldwide. Gilead’s antiviral drug — remdesivir — has been a source of hope for the more than 1.1 million Americans diagnosed with the fast-spreading illness as well as market participants hoping for a swift reopening of the economy.
Gilead
released preliminary results from its clinical trial on its antiviral drug remdesivir last week, showing at least 50% of the COVID-19 patients treated with a five-day dosage of the drug improved. The National Institute of Allergy and Infectious Diseases then released a study that showed Covid-19 patients who took remdesivir usually recovered after 11 days, four days faster than those who didn’t take the drug.
Following these successful trials, the Food and Drug Administration
granted emergency use authorization for the drug to treat Covid-19. That means the drug has not undergone the same review as FDA-approved treatments, but doctors will be allowed to administer remdesivir to patients hospitalized with the disease. All of the drug supply will go to the government to allocate around the nation.
“What we will do is provide that donation to the U.S. government and they will determine — based upon things like ICU beds, where the course of the epidemic is in the United States — they will begin shipping tens of thousands of treatment courses out early this week and be adjusting that as the epidemic shifts and evolves in different parts, in different cities in the United States,” O’Day added.
Gilead expects to produce more than 140,000 rounds of its 10-day treatment regimen by the end of May and anticipates it can make 1 million rounds by the end of this year.
